// App-Quantinova.ai

1057 : Clinical Benefit of Crenolanib, with or without Salvage Chemotherapy, in Multiply Relapsed, FLT3 Mutant AML Patients after Prior Treatment with Gilteritinib

Researchers

Presenter

  • Aaron D Goldberg

Principal Investigators

  • Mark B. Geyer

  • Jonathan Kell

  • Eros Di Bona

  • Timothy S. Pardee

  • Rupali Bhave

  • Michael R. Grunwald

  • Giovanni Marconi

  • Yijia Wang

  • Asif Pathan

  • Boo Messahel

Medical Centers

  • Department of Medicine, Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY

  • Department of Medicine, Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY

  • Dept. of Haematology, University Hospital of Wales, Cardiff, United Kingdom

  • Hematology Department, San Bortolo Hospital, Azienda ULSS8 "Berica" di Vicenza, Vicenza, Italy

  • Comprehensive Cancer Center of Wake Forest Baptist Health, Winston Salem, NC

  • Comprehensive Cancer Center of Wake Forest Baptist Health, Winston Salem, NC

  • Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute/Carolinas HealthCare System, Charlotte, NC

  • Istituto di Ematologia e Oncologia Medica "Lorenzo e Ariosto Seràgnoli" Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy

  • Arog Pharmaceuticals, Plano, TX

Locations

  • United States

  • United Kingdom

  • Italy

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • Fms related tyrosine kinase 3

Drug/Treatment

  • gilteritinib

  • Crenolanib

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved